ArticleChemical research in toxicology2014
Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time.
Article in Chemical research in toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review.Cancer journal (Sudbury, Mass.)Pooled it
- Racial and ethnic differences in HPV-related cancer incidence in the United States, 2001-2020.Journal of the National Cancer Institute · 2025Article
- Neoadjuvant chemoimmunotherapy in patients with locally advanced squamous head and neck cancer: A retrospective study.Frontiers in oncology · 2025Article
- Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13Cancer immunology, immunotherapy : CII · 2024Article
- Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Two brothers with human papillomavirus-positive oropharyngeal squamous cell carcinoma of the tonsil: A case report.SAGE open medical case reports · 2024Article
- Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile.Ecancermedicalscience · 2024Article
- Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.Tissue engineering. Part C, Methods · 2023Review
- Review
- Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma.Cancers · 2023Article
- Article
- Article
- Trends in Oropharyngeal Cancer Incidence Among Adult Men and Women in the United States From 2001 to 2018.Frontiers in oncology · 2022Article
- Decreased CD1a + and CD83 + cells in tonsillar squamous cell carcinoma regardless of HPV status.Journal of applied oral science : revista FOB · 2022Article
- Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016.Cancer medicine · 2021Article
- Prehabilitation in head and neck cancer patients: a literature review.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2021Review
- Article
- Article
- An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma.Cell reports · 2019Article
- Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region.Journal of global oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Human papillomaviruses (HPVs) are involved in approximately 5% of all human cancer. Although initially recognized for causing nearly all cases of cervical carcinoma, much data has now emerged implicating HPVs as a causal factor in other anogenital cancers as well as a subset of head and neck squamous cell carcinomas (HNSCCs), most commonly oropharyngeal cancers. Numerous clinical trials have demonstrated that patients with HPV+ oropharyngeal squamous cell carcinoma (OPSCC) have improved survival compared to patients with HPV- cancers. Furthermore, epidemiological evidence shows the incidence of OPSCC has been steadily rising over time in the United States. It has been proposed that an increase in HPV-related OPSCCs is the driving force behind the increasing rate of OPSCC. Although some studies have revealed an increase in HPV+ head and neck malignancies over time in specific regions of the United States, there has not been a comprehensive study validating this trend across the entire country. Therefore, we undertook this meta-analysis to assess all literature through August 2013 that reported on the prevalence of HPV in OPSCC for patient populations within the United States. The results show an increase in the prevalence of HPV+ OPSCC from 20.9% in the pre-1990 time period to 51.4% in 1990-1999 and finally to 65.4% for 2000-present. In this manner, our study provides further evidence to support the hypothesis that HPV-associated OPSCCs are driving the increasing incidence of OPSCC over time in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.